Agilent unveils experience centre in Hyderabad

The capital investment is part of Agilent’s broader three-to-five-year India growth strategy, which includes expanding its footprint, deepening customer partnerships

Agilent Technologies announced the inauguration of its new Biopharma Experience Centre in Hyderabad, Telangana. The centre was inaugurated by Duddila Sridhar Babu, Minister for Information Technology, Electronics, Communications, and Industries, Government of Telangana, in the presence of Agilent President and CEO Padraig McDonnell, along with senior leaders from India’s pharmaceutical and biopharma sectors.

The new Agilent Biopharma Experience Centre in Hyderabad presents a major opportunity to accelerate the city’s leadership in life sciences and healthcare innovation. Designed to support the full drug development journey, the centre brings together advanced lab technologies, expert training, and regulatory-ready workflows to help researchers, scientists, and companies develop high-quality, life-saving medicines faster and more efficiently. It offers end-to-end solutions across key modalities such as chromatography, mass spectrometry, cell analysis, and lab informatics, allowing companies to simulate real lab environments, test for quality and compliance, and co-create market-ready solutions tailored to both Indian and global needs.

“India is a strategic growth market for Agilent, and Hyderabad is at the forefront of biopharma innovation,” said Padraig McDonnell, CEO, Agilent Technologies. “Our future will be defined by continued innovation and a relentless focus on our customers. This new centre reflects our commitment to delivering integrated solutions that help bring life-changing therapies to market faster and more efficiently. It also reinforces our support for the ‘Make-in-India’ initiative by empowering local innovation, nurturing talent, and enabling scalable, affordable, and sustainable solutions.”

Sridhar Babu said, “With a strong talent base and a clear focus on innovation, we are building a future-ready healthcare system. The launch of the Agilent Biopharma Experience Centre is a significant milestone in strengthening Telangana’s position as a global leader in life sciences, and a valuable addition to our expanding innovation-driven ecosystem.”

The capital investment is part of Agilent’s broader three-to-five-year India growth strategy, which includes expanding its footprint, deepening customer partnerships, and positioning India as a strategic hub in Agilent’s global innovation and profitability roadmap. The India Solution Centre in Manesar, launched earlier this year, further reflects this ongoing commitment—contributing to Agilent’s efforts to enhance its presence and capabilities in one of its fastest-growing, high-priority markets globally.

“Agilent is already working closely with many of India’s leading biopharma companies,” added McDonnell. “With this centre, we aim to strengthen those relationships and co-create solutions that meet the evolving needs of the Indian and global markets.”